AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

But that doesn't mean they'll be spared election noise. AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie ...

After hours: September 20 at 7:59 PM EDT Loading Chart for ABBV ...